97¹ú¼Ê

EN
ÐÂÎÅÖÐÐÄ

»Ý¼°¸ü¶à»¼Õߣ¡ÊæËÙ´ï?·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÄÉÈë¹ú¼ÒÒ½±£Ä¿Â¼

Ðû²¼Ê±¼ä : 2024-11-29

97¹ú¼Ê¡¤(ÖйúÇø)¼¯ÍŹٷ½ÍøÕ¾

 

11ÔÂ28ÈÕ £¬¹ú¼ÒÒ½Áưü¹Ü¾Ö¡¢ÈËÁ¦×ÊÔ´ºÍÉç»á°ü¹Ü²¿ÕýʽÐû²¼ÁË¡¶¹ú¼Ò»ù±¾Ò½Áưü¹Ü¡¢¹¤É˰ü¹ÜºÍÉúÓý°ü¹ÜҩƷĿ¼(2024Äê)¡·¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ¾­Ì¸ÅÐÊ״α»ÄÉÈë¹ú¼ÒÒ½±£Ä¿Â¼¡£Ð°æÄ¿Â¼½«ÓÚ2025Äê1ÔÂ1ÈÕÕýʽʵÑé¡£

˵Ã÷: E:\»ôÇÉÕä\3.ÆóÒµÐû´«\3.¿¯Îï\ÄÚ¿¯\ÄÚ¿¯Îļþ\2024Äê\12Ô¿¯\10.·Çŵ±´ÌؽøÈëÒ½±£\΢ÐŽØÍ¼_20241128114133.png

 

ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ

       ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÊô±´ÌØÀàѪ֬µ÷ÀíÒ© £¬Í¨¹ýÒÖÖÆ¼«µÍÃܶÈÖ¬ÂѰ׵¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥µÄÌìÉú²¢Í¬Ê±Ê¹ÆäÆÊÎö´úлÔö¶à £¬½µµÍѪµÍÃܶÈÖ¬ÂѰ׵¨¹Ì´¼ºÍ¸ÊÓÍÈýõ¥£»»¹Ê¹ÔØÖ¬ÂѰ×A1ºÍA11ÌìÉúÔöÌí £¬´Ó¶øÔö¸ß¸ßÃܶÈÖ¬ÂѰ׵¨¹Ì´¼¡£ÊæËÙ´ï®·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒÓÅ»¯µ¨¼îÑνṹ £¬¾ßÓнϺõÄË®ÈÜÐÔ £¬ÏÔÖøÌáÉýÁËÉúÎïʹÓöÈ[1]£»Ò»´ÎÒ»Á££¨135mg£©,Ò»ÌìÒ»´Î £¬ÎÞÐèÓë²Íͬ·þ £¬ÌáÉýÓÃÒ©±ãµ±ÐÔ[2]¡£¿ÉÖ±½ÓÔÚÌåÄÚʩչ×÷Óà £¬ÎÞÐè¾­ÓɸÎÔàÊ×¹ý´úл £¬´Ó¶ø¿É½µµÍ¸ÎÔà¼ç¸º[1]¡£ËµÃ÷ÊéÖ¸³ö £¬±¾Æ·ÓëËûÍ¡ÀàÒ©ÎïÍŽáʹÓÃÎÞÐèµ÷½â±¾Æ·»òÊÊÓÃÒ©ÎïµÄ¼ÁÁ¿¡£

 

ºÏ×÷×ÉѯÈÈÏß:4001833668

¿ÉɨÂë¹ÒºÅºÏ×÷ÐÅÏ¢

97¹ú¼Ê¡¤(ÖйúÇø)¼¯ÍŹٷ½ÍøÕ¾

²Î¿¼×ÊÁÏ£º

[1]     Elisavet Moutzouri ,Anastazia Kei,Moses S elisaf ,Haralampos J Milionis.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.Vascular Health and Risk Management 2010:6 525–539.

[2]   ·Çŵ±´ÌØËᵨ¼î»ºÊͽºÄÒ˵Ã÷Êé.

Ïà¹ØÐÂÎÅ

2026-02-03

ͨ¸æ | 97¹ú¼Ê°¢ÂØì¢ËáÄÆ¿Ú·þÈÜÒº»ñÅúÉÏÊÐ

2026-01-08

ͨ¸æ | 97¹ú¼ÊÁ×Ëá°Â˾ËûΤ½ºÄÒйæ¸ñ»ñÅúÉÏÊÐ

2025-12-29

97¹ú¼Ê²Î¹ÉÈ«ÇòÁìÏȵķÖ×Ó½ºÀàÐÂÐÍÂѰ׽µ½â¼ÁÑз¢¹«Ë¾´ï¸èÉúÎïDegron Therapeutics

Ïàʶ¸ü¶à
ÍøÕ¾µØÍ¼